SEC Form 4 · accession 0001209191-18-000993
Alaunos Therapeutics, Inc. · TCRT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Laurence James Neil Cooper
Officer — Chief Executive Officer
Period of report
Dec 29, 2017
Accepted (ET)
Jan 3, 2018 · 4:54 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001107421
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 29, 2017 | A | 348,000 | $0.00 | A | 1,431,731 | D | |
| Common StockF2 | Dec 30, 2017 | F | 26,178 | $4.14 | D | 1,405,553 | D | |
| Common StockF2 | Dec 31, 2017 | F | 16,157 | $4.14 | D | 1,389,396 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1116,000 shares shall vest on each of 12/29/2018, 12/29/2019 and 12/29/2020.
- F2Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants.